Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s):  MYCOF

Healthcare Advertising Agencies
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Mydecine Innovations Group Inc > Stop taking everything viTelInA says so seriously
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by akv1955on Feb 05, 2021 9:47am
70 Views
Post# 32482617

RE:RE:Stop taking everything viTelInA says so seriously

RE:RE:Stop taking everything viTelInA says so seriouslyGod bless your soul. You say you have numerous decades of expereince and yet you reply like an emotional teenager...  You also said that you own a whack amount in every stock?!? I’m saying is how cam anyone even takenyour seriously when you say stuff like this?! Your posts make me cringe and the sad part is that you comment and post on her religiously.

If you can really show everyone on this board some truthbin your posts then send us your linkedin so we can see your background in all this.

Cheers 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities